HANDOK (002390) Fundamentals 2026 — Revenue Analysis | SniperIQ
HANDOK (002390) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩108.7B, trading at ₩8370.00 on the KSC. This SniperIQ fundamentals page covers HANDOK's valuation, profitability (net margin -0.5%), revenue (₩535.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HANDOK's market cap?
HANDOK (002390) has a market capitalization of approximately ₩108.7B, trading at ₩8370.00 on the KSC. Market cap moves with the live share price.
What is HANDOK's P/E ratio?
HANDOK's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HANDOK?
HANDOK runs a net profit margin of -0.5%, a gross margin of 28.6%, and an operating margin of 1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HANDOK generate?
HANDOK reported revenue of ₩535.1B for fiscal year 2025, with net income of -₩2.2B and earnings per share (EPS) of -162.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HANDOK pay a dividend?
HANDOK offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is HANDOK financially healthy?
HANDOK carries a debt-to-equity ratio of 1.42x and a current ratio of 0.77x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HANDOK a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HANDOK (002390) the key facts are: market cap ₩108.7B, revenue ₩535.1B, 52-week range 6460-13460. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HANDOK's full fundamentals live
Get HANDOK's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.